IDRA Idera Pharmaceuticals Inc.

2.23
-0.03  -1%
Previous Close 2.26
Open 2.25
Price To book 4.46
Market Cap 333678876
Shares 149,631,783
Volume 566,541
Short Ratio 17.15
Av. Daily Volume 951,702

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 basket trial to be initiated 2H 2017.
IMO-2125
Cancer - solid tumors
Phase 1/2 data released September 10, 2017. 6/9 disease control with one CR. Phase 3 trial to be initiated 1Q 2018.
IMO-2125
Cancer - melanoma
Development suspended - September 2016.
IMO-8400
Waldenström’s Macroglobulinemia
Development suspended - September 2016.
IMO-8400
Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2 initiated November 2015. Enrollment to be completed by the end of 2017 with data due 1H 2018.
IMO-8400
Dermatomyositis

Latest News

  1. 3 Small-Cap Biotech Stocks to Buy This Fall
  2. Is It Time To Buy Idera Pharmaceuticals Inc (IDRA)?
  3. ETFs with exposure to Idera Pharmaceuticals, Inc. : September 19, 2017
  4. Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
  5. Idera Pharmaceuticals (IDRA) Jumps: Stock Rises 14.4%
  6. Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and Idera Pharmaceuticals
  7. Here's Why Idera Pharmaceuticals, Inc. Is Surging Today
  8. Achillion Shares Are Plunging on Termination of Hepatitis C Pact
  9. US STOCKS-Wall St set for relief rally as Irma, N.Korea fears ease
  10. Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate (ORR) of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy
  11. Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment in Combination with Ipilimumab that Demonstrates Induction of Durable Anti-tumor Responses Associated with Tumor-Specific Memory
  12. Idera to Host Investor Conference Call on Monday, September 11, 2017 at 9:00 A.M. E.T.
  13. Idera to Present at the 2017 Wedbush PacGrow Healthcare Conference
  14. Idera reports 2Q loss
  15. Idera Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
  16. ETFs with exposure to Idera Pharmaceuticals, Inc. : July 11, 2017
  17. 3 Stocks That Could Double Your Money
  18. 3 Stocks to Watch on Friday: Bed Bath & Beyond Inc. (BBBY), Sonic Corporation (SONC) and Idera Pharmaceuticals Inc (IDRA)